454 related articles for article (PubMed ID: 20083156)
1. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.
Frank-Raue K; Rondot S; Raue F
Mol Cell Endocrinol; 2010 Jun; 322(1-2):2-7. PubMed ID: 20083156
[TBL] [Abstract][Full Text] [Related]
2. Multiple endocrine neoplasia type 2: 2007 update.
Raue F; Frank-Raue K
Horm Res; 2007; 68 Suppl 5():101-4. PubMed ID: 18174721
[TBL] [Abstract][Full Text] [Related]
3. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Frank-Raue K; Rondot S; Schulze E; Raue F
Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
[TBL] [Abstract][Full Text] [Related]
4. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
5. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
[TBL] [Abstract][Full Text] [Related]
6. [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].
Frank-Raue K; Heimbach C; Rondot S; Usadel KH; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
Dtsch Med Wochenschr; 2003 Sep; 128(39):1998-2002. PubMed ID: 14508694
[TBL] [Abstract][Full Text] [Related]
7. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
8. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
10. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC.
Chiefari E; Chiarella R; Crocetti U; Tardio B; Arturi F; Russo D; Trischitta V; Filetti S; Zingrillo M
Horm Metab Res; 2001 Jan; 33(1):52-6. PubMed ID: 11280716
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management.
Raue F; Frank-Raue K
Hormones (Athens); 2009; 8(1):23-8. PubMed ID: 19269918
[TBL] [Abstract][Full Text] [Related]
13. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
14. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
[TBL] [Abstract][Full Text] [Related]
15. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients.
Fernández RM; Navarro E; Antiñolo G; Ruiz-Ferrer M; Borrego S
Int J Mol Med; 2006 Apr; 17(4):575-81. PubMed ID: 16525712
[TBL] [Abstract][Full Text] [Related]
17. Current approaches to medullary thyroid carcinoma, sporadic and familial.
Fialkowski EA; Moley JF
J Surg Oncol; 2006 Dec; 94(8):737-47. PubMed ID: 17131404
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
[TBL] [Abstract][Full Text] [Related]
19. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
[TBL] [Abstract][Full Text] [Related]
20. Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds.
Dvorakova S; Vaclavikova E; Ryska A; Cap J; Vlcek P; Duskova J; Kodetova D; Holub V; Novak Z; Bendlova B
Exp Clin Endocrinol Diabetes; 2006 Apr; 114(4):192-6. PubMed ID: 16705552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]